Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Antonio M Almeida, Thomas Prebet, Raphael Itzykson...
https://pubmed.ncbi.nlm.nih.gov/28420120/Actively Recruiting
Led by Arbeitsgemeinschaft medikamentoese Tumortherapie · Updated on 2025-04-10
3000
Participants Needed
16
Research Sites
52 weeks
Total Duration
Researchers are collecting data from patients with myeloid diseases, including myelodysplastic syndromes MDS, chronic myelomonocytic leukemia CMML, acute myeloid leukemia AML, and primary myelofibrosis PMF. This observational study gathers real-world information about how these diseases are managed in Austria and potentially other countries in the future. It aims to better understand treatment patterns and outcomes for these conditions. The study uses an electronic case report form where clinical trial staff and physicians enter routine medical data already recorded in patient charts. Optional quality of life assessments, such as EQ-5D-5L and EORTC QLQ-C30 questionnaires, may also be collected with proper approval. There are no experimental treatments involved, as it is a non-interventional registry. Participants provide informed consent and their medical records are reviewed over time to assess treatment types, responses, survival, safety, and quality of life. The study monitors these outcomes until completion, which is expected within about 100 months. This allows researchers to observe long-term patterns and effects of treatments in everyday clinical practice.
CONDITIONS
Austrian Myeloid Registry
L
Lisa Pleyer, MD
D
Daniela Wolkersdorfer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Arbeitsgemeinschaft medikamentoese Tumortherapie
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 100 months until study completion
Participants who undergo routine care are observed to collect clinical data related to their myeloid disease. Optional quality of life assessments may be completed.
Data collection occurs during routine clinical visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Antonio M Almeida, Thomas Prebet, Raphael Itzykson...
https://pubmed.ncbi.nlm.nih.gov/28420120/Lisa Pleyer, Hartmut Döhner, Hervé Dombret...
https://pubmed.ncbi.nlm.nih.gov/28212292/Lukas Weiss, Thomas Melchardt, Daniel Neureiter...
https://pubmed.ncbi.nlm.nih.gov/21730268/Lisa Pleyer, Reinhard Stauder, Sonja Burgstaller...
https://pubmed.ncbi.nlm.nih.gov/23627920/Florian Huemer, Lukas Weiss, Viktoria Faber...
https://pubmed.ncbi.nlm.nih.gov/29383443/Lisa Pleyer, Michael Leisch, Alexandra Kourakli...
https://pubmed.ncbi.nlm.nih.gov/33513373/Lisa Pleyer, Sonja Heibl, Christoph Tinchon...
https://pubmed.ncbi.nlm.nih.gov/36900181/Lisa Pleyer, Ulrich Germing, Wolfgang R Sperr...
https://pubmed.ncbi.nlm.nih.gov/24522248/Thomas Melchardt, Lukas Weiss, Lisa Pleyer...
https://pubmed.ncbi.nlm.nih.gov/24260071/Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder...
https://pubmed.ncbi.nlm.nih.gov/27084507/Arbeitsgemeinschaft medikamentoese Tumortherapie
Lead Sponsor